HEM Hemosense

HemoSense, Inc. (AMEX:HEM) today announced that it has an agreement with CheckUps, a provider of retail-based, non-emergency, walk-in medical facilities, to supply its INRatio� PT/INR testing system to all CheckUps medical clinics located in Wal-Mart stores, including 20 new clinics scheduled to open in the southeast by the end of 2006. CheckUps provides a range of diagnostic and treatment services performed by nurse practitioners and physician assistants. �We are delighted to have been selected by CheckUps as the supplier of blood coagulation monitoring equipment for their new Wal-Mart-based clinics,� said Jim Merselis, President and CEO of HemoSense. �Patients on the blood thinning medicine warfarin should check their blood coagulation levels on a frequent basis, and trips to a doctor or traditional testing facility can be time-consuming and costly. For those patients who currently do not perform home-tests with INRatio, the availability of a PT/INR test with a qualified healthcare professional at their local Wal-Mart-based CheckUps Clinic can be a significant convenience.� The INRatio system consists of a small, portable monitor and disposable test strips that provide a quick and accurate measurement of blood-clotting time, known as a PT/INR value. INRatio is an easy-to-use system that is available to the more than 3 million people in the United States and 7 million people worldwide who take warfarin daily. In 2003, more than 21 million U.S. prescriptions were written for warfarin. About HemoSense HemoSense develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient�s warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, the statements regarding the Company�s ability to raise awareness of the availability of INRatio for patients managing their warfarin levels in the areas served by select Wal-Mart locations are forward looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary, expectations and are subject to risks and uncertainties which may cause the actual results to differ materially from the statements contained herein. Further information on the Company's business and risk factors are detailed in its filings with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2006 filed on August 11, 2006. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. HemoSense� and INRatio� are registered trademarks of HemoSense, Inc. HemoSense, Inc. (AMEX:HEM) today announced that it has an agreement with CheckUps, a provider of retail-based, non-emergency, walk-in medical facilities, to supply its INRatio(R) PT/INR testing system to all CheckUps medical clinics located in Wal-Mart stores, including 20 new clinics scheduled to open in the southeast by the end of 2006. CheckUps provides a range of diagnostic and treatment services performed by nurse practitioners and physician assistants. "We are delighted to have been selected by CheckUps as the supplier of blood coagulation monitoring equipment for their new Wal-Mart-based clinics," said Jim Merselis, President and CEO of HemoSense. "Patients on the blood thinning medicine warfarin should check their blood coagulation levels on a frequent basis, and trips to a doctor or traditional testing facility can be time-consuming and costly. For those patients who currently do not perform home-tests with INRatio, the availability of a PT/INR test with a qualified healthcare professional at their local Wal-Mart-based CheckUps Clinic can be a significant convenience." The INRatio system consists of a small, portable monitor and disposable test strips that provide a quick and accurate measurement of blood-clotting time, known as a PT/INR value. INRatio is an easy-to-use system that is available to the more than 3 million people in the United States and 7 million people worldwide who take warfarin daily. In 2003, more than 21 million U.S. prescriptions were written for warfarin. About HemoSense HemoSense develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, the statements regarding the Company's ability to raise awareness of the availability of INRatio for patients managing their warfarin levels in the areas served by select Wal-Mart locations are forward looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary, expectations and are subject to risks and uncertainties which may cause the actual results to differ materially from the statements contained herein. Further information on the Company's business and risk factors are detailed in its filings with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2006 filed on August 11, 2006. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. HemoSense(R) and INRatio(R) are registered trademarks of HemoSense, Inc.